Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9292
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYang, Chen-Hsun-
dc.contributor.authorKuo, Shu-Fang-
dc.contributor.authorChen, Fang-Ju-
dc.contributor.authorLee, Chen-Hsiang-
dc.date.accessioned2024-12-19T03:13:32Z-
dc.date.available2024-12-19T03:13:32Z-
dc.date.issued2023-04-
dc.identifier.citationOriginal Articleen_US
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9292-
dc.description.abstractAbstract Background/Purpose: Nocardiosis is an uncommon infectious disease. This study aimed to assess the clinical outcome of patients with nocardiosis and examine the antimicrobial susceptibility profiles of Nocardia spp. isolated. Methods: We retrospectively reviewed the medical records of all inpatients diagnosed with nocardiosis between 2011 and 2021. The identification of Nocardia spp. at the species level was performed with the use of MALDI-TOF and 16S rRNA assays. The antimicrobial susceptibility of Nocardia spp. was performed using the microbroth dilution method. Factors associated with 90-day all-cause mortality were identified in multivariate logistic regression analysis. Results: Of 60 patients with nocardiosis in the 11-year study period, the lungs (55.0%) were the most common site of involvement, followed by the skin and soft tissue (45.0%). Twenty-two patients (36.7%) died within 90 days following the diagnosis. All of the Nocardia isolates were susceptible to trimethoprim-sulfamethoxazole, linezolid, and amikacin, whereas more than 70% of the isolates were not susceptible to ciprofloxacin, imipenem-cilastatin, moxifloxacin, cefepime, and clarithromycin. Nocardiosis involving the lungs (relative risk [RR], 9.99; 95% confidence interval [CI], 1.52e65.50; p Z 0.02), nocardiosis involving the skin and soft tissue (RR, 0.15; 95% CI, 0.02e0.92; p Z 0.04), and treatment with trimethoprim-sulfamethoxazole (RR, 0.14; 95% CI, 0.03e0.67; p Z 0.01) were independently associated with 90-day all-cause mortality. Conclusions: Nocardia spp. identified between 2011 and 2021 remained fully susceptible to trimethoprim-sulfamethoxazole, linezolid, and amikacin. Nocardiosis of the lungs, skin and soft tissue infection, and treatment with trimethoprim-sulfamethoxazole were independently associated with 90-day all-cause mortality.en_US
dc.language.isoen_USen_US
dc.publisherElsevier Taiwan LLCen_US
dc.subjectNocardiosisen_US
dc.subjectAntimicrobial susceptibilityen_US
dc.subjectMicrobroth dilution methoden_US
dc.subjectCarbapenemen_US
dc.subjectTrimethoprimsulfamethoxazoleen_US
dc.titleClinical manifestations and outcome of nocardiosis and antimicrobial susceptibility of Nocardia species in southern Taiwan, 2011e2021en_US
dc.typeArticleen_US
Appears in Collections:VOL 56 NO 2 2023

Files in This Item:
File Description SizeFormat 
382-391.pdf703.38 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.